The study investigates the role of activated T cells in bone loss and joint destruction through the osteoprotegerin ligand (OPGL). Activated T cells produce OPGL, which can directly trigger osteoclastogenesis, leading to bone resorption. In vivo, systemic activation of T cells results in increased osteoclastogenesis and bone loss. In a rat model of adjuvant arthritis, blocking OPGL with osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These findings suggest that activated T cells are key regulators of bone physiology and that inhibiting OPGL activity can prevent cartilage destruction, a critical step in arthritis pathogenesis. The study also notes that spontaneous T-cell lymphomas in mice express high levels of OPGL and can support osteoclastogenesis.The study investigates the role of activated T cells in bone loss and joint destruction through the osteoprotegerin ligand (OPGL). Activated T cells produce OPGL, which can directly trigger osteoclastogenesis, leading to bone resorption. In vivo, systemic activation of T cells results in increased osteoclastogenesis and bone loss. In a rat model of adjuvant arthritis, blocking OPGL with osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation. These findings suggest that activated T cells are key regulators of bone physiology and that inhibiting OPGL activity can prevent cartilage destruction, a critical step in arthritis pathogenesis. The study also notes that spontaneous T-cell lymphomas in mice express high levels of OPGL and can support osteoclastogenesis.